OR WAIT 15 SECS
September 25, 2015.
A drug price hike like that of the one seen in the highly publicized case of Turing Pharmaceuticals' Daraprim is prompting a public outcry and is demonizing the industry for those who see Martin Shkreli as representative of all pharmaceutical executives. But capping drug price increases may affect actual patient costs less than imagined, and may have a bigger impact on pharmacy benefit managers and insurance companies.
In this BioPharm International report, Randi Hernandez looks at arguments that say Clinton's drug price plan could actually give manufacturers more pricing power.